TransMedics Group, Inc. (TMDX)

Market Cap	3.72B
Revenue (ttm)	488.23M
Net Income (ttm)	48.95M
Shares Out	33.83M
EPS (ttm)	1.41
PE Ratio	78.06
Forward PE	59.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	436,098
Open	110.80
Previous Close	105.60
Day's Range	109.73 - 111.70
52-Week Range	55.00 - 177.37
Beta	2.05
Analysts	Buy
Price Target	129.88 (+18.11%)
Earnings Date	Jul 30, 2025

About TMDX

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung trans...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 2, 2019
• Employees: 728
• Stock Exchange: NASDAQ
• Ticker Symbol: TMDX
• Website: https://www.transmedics.com

Analyst Summary

According to 9 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price target is $129.88, which is an increase of 18.11% from the latest price.

Price Target

$129.88

(18.11% upside)

Analyst Consensus: Buy